Literature DB >> 23477848

Prevalence, chronicity, burden and borders of bipolar disorder.

Andrea Fagiolini1, Rocco Forgione, Mauro Maccari, Alessandro Cuomo, Benedetto Morana, Mario Catena Dell'Osso, Francesca Pellegrini, Alessandro Rossi.   

Abstract

Bipolar disorder (BD) has traditionally been thought of as an episodic condition, characterized by periods of hypomania/mania and depression. However, evidence is accumulating to suggest that this condition is associated with significant chronicity. For a large proportion of patients with BD, residual, sub-syndromal symptoms persist between major syndromal episodes, and studies have shown that many patients with bipolar disorder are symptomatic for approximately 50% of the time over follow-up periods of greater than 10 years. Moreover, while the prevalence of BD has been estimated to be around 1-2%, there is growing evidence that this may be a substantial underestimation. There are a number of reasons for this potential underestimation, including difficulties in diagnosis. Adding to the burden of BD is the issue of comorbidity, with an increased prevalence of many chronic conditions in those with a primary diagnosis of BD. Conversely, for many patients with chronic conditions, both medical and psychiatric, BD frequently exists as a comorbid secondary diagnosis. This issue of comorbidity complicates estimates of use of pharmaceutical agents for BD, such as mood stabilizers, which are known to be used off-label in conditions such as borderline personality or substance use disorder. We speculate that such off-label prescribing may not be truly off-label but may be instead fully justified by an overlooked secondary diagnosis of BD. Finally, we discuss the association of bipolar disorder with a significant economic burden, to the individual and to society, both due to the direct costs of medical expenditure and indirect costs such as loss of productivity and increased mortality.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23477848     DOI: 10.1016/j.jad.2013.02.001

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  41 in total

1.  Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis.

Authors:  Martha Sajatovic; Daisy Ng-Mak; Caitlyn T Solem; Fang-Ju Lin; Krithika Rajagopalan; Antony Loebel
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

2.  The Prevalence of Bipolar Disorders and Association With Quality of Life in a Cohort of Patients With Multiple Sclerosis.

Authors:  Adalia H Jun-O'Connell; Ankur Butala; Idanis Berrios Morales; Nils Henninger; Kristina M Deligiannidis; Nancy Byatt; Carolina Ionete
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-08-19       Impact factor: 2.198

Review 3.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

4.  An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial.

Authors:  Ellen Frank; Meredith L Wallace; Martica Hall; Brant Hasler; Jessica C Levenson; Carol A Janney; Isabella Soreca; Matthew C Fleming; Joan Buttenfield; Fiona C Ritchey; David J Kupfer
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

5.  Estimating the Prevalence of Serious Mental Illness and Dementia Diagnoses Among Medicare Beneficiaries in the Health and Retirement Study.

Authors:  Maria Teresa Brown; Douglas A Wolf
Journal:  Res Aging       Date:  2017-08-31

Review 6.  Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder.

Authors:  Andrea Fagiolini; Anna Coluccia; Giuseppe Maina; Rocco N Forgione; Arianna Goracci; Alessandro Cuomo; Allan H Young
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

7.  Pharmacologic management of bipolar disorder in a Medicare Advantage population.

Authors:  Hsiang Huang; Jessica L Gören; Ya-Fen Chan; Wayne Katon; Joan Russo; Diane Hogan; Jürgen Unützer
Journal:  Psychosomatics       Date:  2014-04-19       Impact factor: 2.386

8.  A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD.

Authors:  Thilo Deckersbach; Amy T Peters; Louisa G Sylvia; Alexandra K Gold; Pedro Vieira da Silva Magalhaes; David B Henry; Ellen Frank; Michael W Otto; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; David J Miklowitz
Journal:  J Affect Disord       Date:  2016-05-31       Impact factor: 4.839

9.  The Behavioral Approach System (BAS) Model of Vulnerability to Bipolar Disorder: Evidence of a Continuum in BAS Sensitivity across Adolescence.

Authors:  Richard T Liu; Taylor A Burke; Lyn Y Abramson; Lauren B Alloy
Journal:  J Abnorm Child Psychol       Date:  2018-08

Review 10.  Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers.

Authors:  Ather Muneer
Journal:  Psychiatry Investig       Date:  2015-11-20       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.